Multisession radiosurgery for grade 2 (WHO), high risk meningiomas. A phase II clinical trial.
Atypical
Grade 2 meningioma
Hypofractionated stereotactic radiotherapy
Meningioma
Radiosurgery
Radiotherapy
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
17
12
2021
accepted:
23
02
2022
pubmed:
6
4
2022
medline:
10
5
2022
entrez:
5
4
2022
Statut:
ppublish
Résumé
Patients suffering from recurrent and residual grade 2 (WHO) meningiomas after subtotal excision should be considered as high-risk groups with an uncertain prognosis. Adjuvant radiotherapy seems to be the best approach to reduce disease progression. The primary aim of this phase II explorative, monocentric, single arm study was to evaluate the safety of adjuvant multisession radiosurgery (mRS) in this group of patients; the efficacy in terms of tumour local control was the secondary endpoint. Patients recruited from April 2017 to May 2019 were over 18 years old, had a histologically-documented intracranial recurrent or residual Grade 2 meningioma (WHO 2016) and a KPS > 70. Patients with NF2, concomitant neoplasm or pregnancy were excluded. Descriptive statistics were provided for categorical variables. Progression free survival (PFS) was modelled using the Kaplan-Meier method. Twenty-four patients were enrolled. All 24 patients underwent mRS: twenty-two patients received 28 Gy in 4 fractions, 2 patients received 24 Gy in 4 Treatment related adverse events (CTCAE 4.3) were limited to grade 2 in 1 patient (4.1%). At a median follow-up of 28 months, 8 patients (33.3%) had disease progression, either out-of-field or infield, compared with the planning target volume. Considering both infield and out-of-field progressions, 3-year PFS was 47% (95% confidence interval, CI, 22-69%); considering only the infield ones, 3-year PFS was 86% (95% CI 55-96%), and local control at last follow-up was 92%. mRS provides good local control of the tumour volume (TV) and is associated with a low rate of toxicity. These results call for further investigation to confirm favourable outcomes in patients with high-risk meningioma. NCT05081908, October 18, 2021, retrospectively registered.
Identifiants
pubmed: 35378640
doi: 10.1007/s11060-022-03978-w
pii: 10.1007/s11060-022-03978-w
pmc: PMC8979484
doi:
Banques de données
ClinicalTrials.gov
['NCT05081908']
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
397-403Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16(44):iv1-63. https://doi.org/10.1093/neuonc/nou223
doi: 10.1093/neuonc/nou223
pubmed: 25304271
pmcid: 4193675
Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM (2005) Epidemiology of intracranial meningioma. Neurosurgery 57(6):1088–1095. https://doi.org/10.1227/01.NEU.0000188281.91351.B9
doi: 10.1227/01.NEU.0000188281.91351.B9
pubmed: 16331155
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820
doi: 10.1007/s00401-016-1545-1
Zhi M, Girvigian MR, Miller MJ, Chen JC, Schumacher AJ, Rahimian J et al (2019) Long-term outcomes of newly diagnosed resected atypical meningiomas and the role of adjuvant radiotherapy. World Neurosurg 122:e1153–e1161. https://doi.org/10.1016/j.wneu.2018.11.006
doi: 10.1016/j.wneu.2018.11.006
pubmed: 30447464
Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J et al (2015) Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 122(1):4–23. https://doi.org/10.3171/2014.7.JNS131644
doi: 10.3171/2014.7.JNS131644
pubmed: 25343186
pmcid: 5062955
Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, Preusser M, Minniti G, Lund-Johansen M, Lefranc F, Houdart E, Sallabanda K, Le Rhun E, Nieuwenhuizen D, Tabatabai G, Soffietti R, Weller M (2021) EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. https://doi.org/10.1093/neuonc/noab150ù
doi: 10.1093/neuonc/noab150ù
pubmed: 34935978
Pereira BJA, de Almeida AN, Paiva WS, Teixeira MJ, Marie SKN (2019) Impact of radiotherapy in atypical meningioma recurrence: literature review. Neurosurg Rev 42(3):631–637
doi: 10.1007/s10143-018-0959-8
Bagshaw HP, Burt LM, Jensen RL, Suneja G, Palmer CA, Couldwell WT et al (2017) Adjuvant radiotherapy for atypical meningiomas. J Neurosurg 126(6):1822–1828
doi: 10.3171/2016.5.JNS152809
Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamaridès M, Menei P et al (2009) WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol 95(3):367–375
doi: 10.1007/s11060-009-9934-0
Delgado-López PD, Corrales-García EM (2021) Role of adjuvant radiotherapy in atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas: a systematic review. Clin Transl Oncol 23:205–221. https://doi.org/10.1007/s12094-020-02434-3
doi: 10.1007/s12094-020-02434-3
pubmed: 32651886
Rogers CL, Won M, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Galvin J, Fogh SE, Youssef E, Deb N, Kwok Y, Robinson CG, Shu HK, Fisher BJ, Panet-Raymond V, McMillan WG, de Groot JF, Zhang P, Mehta MP (2020) High-risk meningioma: initial outcomes from NRG oncology/RTOG 0539. Int J Radiat Oncol Biol Phys 106(4):790–799. https://doi.org/10.1016/j.ijrobp.2019.11.028
doi: 10.1016/j.ijrobp.2019.11.028
pubmed: 31786276
Graffeo CS, Leeper HE, Perry A, Uhm JH, Lachance DJ, Brown PD et al (2017) Revisiting adjuvant radiotherapy after gross total resection of World Health Organization grade II meningioma. World Neurosurg 103:655–663. https://doi.org/10.1016/j.wneu.2017.04.095
doi: 10.1016/j.wneu.2017.04.095
pubmed: 28450233
Ryu HS, Moon KS, Lee KH et al (2017) Recurred intracranial meningioma: a retrospective analysis for treatment outcome and prognostic factor. Brain Tumor Res Treat 5(2):54–63. https://doi.org/10.14791/btrt.2017.5.2.54
doi: 10.14791/btrt.2017.5.2.54
pubmed: 29188205
pmcid: 5700028
Lee G, Lamba N, Niemierko A, Kim DW, Chapman PH, Loeffler JS, Curry WT, Martuza RL, Oh KS, Barker FG 2nd, Shih HA (2020) Adjuvant radiotherapy versus surveillance following surgical resection of atypical meningiomas. Int J Radiat Oncol Biol Phys 109(1):252–266. https://doi.org/10.1016/j.ijrobp.2020.08.015
doi: 10.1016/j.ijrobp.2020.08.015
pubmed: 32777336
Keric N, Kalasauskas D, Freyschlag CF, Gempt J, Misch M, Poplawski A, Lange N, Ayyad A, Thomé C, Vajkoczy P, Meyer B, Ringel F (2020) Impact of postoperative radiotherapy on recurrence of primary intracranial atypical meningiomas. J Neurooncol 146(2):347–355. https://doi.org/10.1007/s11060-019-03382-x
doi: 10.1007/s11060-019-03382-x
pubmed: 31900826
Reddy AK, Ryoo JS, Denyer S, McGuire LS, Mehta AI (2019) Determining the role of adjuvant radiotherapy in the management of meningioma: a Surveillance, Epidemiology, and End Results analysis. Neurosurg Focus 46(6):E3. https://doi.org/10.3171/2019.3.FOCUS1971
doi: 10.3171/2019.3.FOCUS1971
pubmed: 31153148
Weber DC, Ares C, Villa S, Peerdeman SM, Renard L, Baumert BG et al (2018) Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: a phase-II parallel non-randomized and observation study (EORTC 22042–26042). Radiother Oncol 128(2):260–265
doi: 10.1016/j.radonc.2018.06.018
Kaur G, Sayegh ET, Larson A, Bloch O, Madden M, Sun MZ et al (2014) Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro Oncol 16(5):628–636. https://doi.org/10.1093/neuonc/nou025
doi: 10.1093/neuonc/nou025
pubmed: 24696499
pmcid: 3984561
Valery CA, Faillot M, Lamproglou I, Golmard JL, Jenny C, Peyre M, Mokhtari K, Mazeron JJ, Cornu P, Kalamarides M (2016) Grade II meningiomas and Gamma Knife radiosurgery: analysis of success and failure to improve treatment paradigm. J Neurosurg 125(Suppl 1):89–96. https://doi.org/10.3171/2016.7.GKS161521
doi: 10.3171/2016.7.GKS161521
pubmed: 27903189
Liu X, Shan B, Wang M, Xu J (2018) World Health Organization Grade II Meningiomas: the role of adjuvant/salvage gamma knife surgery after initial surgery and prognostic factor assessment. World Neurosurg 109:e352–e362. https://doi.org/10.1016/j.wneu.2017.09.178
doi: 10.1016/j.wneu.2017.09.178
pubmed: 28987849
Kim M, Cho YH, Kim JH, Kim CJ, Roh SW, Kwon DH (2020) Role of gamma knife radiosurgery for recurrent or residual World Health Organization grade II and III intracranial meningiomas. Br J Neurosurg 34(3):239–245. https://doi.org/10.1080/02688697.2020.1726285
doi: 10.1080/02688697.2020.1726285
pubmed: 32054320
Cohen-Inbar O, Lee CC, Sheehan JP (2016) The contemporary role of stereotactic radiosurgery in the treatment of meningiomas. Neurosurg Clin N Am 27(2):215–228
doi: 10.1016/j.nec.2015.11.006
Shepard MJ, Xu Z, Kearns K, Li C, Chatrath A, Sheehan K, Sheehan D, Faramand A, Niranjan A, Kano H, Gurewitz J, Bernstein K, Liscak R, Guseynova K, Grills IS, Parzen JS, Cifarelli CP, Rehman AA, Atik A, Bakhsheshian J, Zada G, Chang E, Giannotta S, Speckter H, Wu HM, Kondziolka D, Golfinos JG, Mathieu D, Lee CC, Warnick RE, Lunsford LD, Sheehan JP (2021) Stereotactic radiosurgery for atypical (World Health Organization II) and anaplastic (World Health Organization III) meningiomas: results from a multicenter. Int Cohort Study Neurosurg 88(5):980–988. https://doi.org/10.1093/neuros/nyaa553
doi: 10.1093/neuros/nyaa553
Helis CA, Hughes RT, Cramer CK, Tatter SB, Laxton AW, Bourland JD, Munley MT, Chan MD (2020) Stereotactic radiosurgery for atypical and anaplastic meningiomas. World Neurosurg 144:e53–e61. https://doi.org/10.1016/j.wneu.2020.07.211
doi: 10.1016/j.wneu.2020.07.211
pubmed: 32758657
Acker G, Meinert F, Conti A, Kufeld M, Jelgersma C, Nguyen P et al (2019) Image-guided robotic radiosurgery for treatment of recurrent grade II and III meningiomas. A Single Center Study. World Neurosurg 131:e96–e107. https://doi.org/10.1016/j.wneu.2019.07.058
doi: 10.1016/j.wneu.2019.07.058
pubmed: 31306844
Zhang M, Ho AL, D’Astous M, Pendharkar AV, Choi CYH, Thompson PA et al (2016) CyberKnife stereotactic radiosurgery for atypical and malignant meningiomas. World Neurosurg 91:574-581.e1. https://doi.org/10.1016/j.wneu.2016.04.019
doi: 10.1016/j.wneu.2016.04.019
pubmed: 27108030
Vernimmen FJ, Slabbert JP (2010) Assessment of the a/ß ratios for arteriovenous malformations, meningiomas, acoustic neuromas, and the optic chiasma. Int J Radiat Biol 86(6):486–498. https://doi.org/10.3109/09553001003667982
doi: 10.3109/09553001003667982
pubmed: 20470198
Pinzi V, Bisogno I, Prada F, Ciusani E, Fariselli L (2018) Radiotherapy of meningioma: a treatment in need of radiobiological research. Int J Radiat Biol 94(7):621–627. https://doi.org/10.1080/09553002.2018.1478157
doi: 10.1080/09553002.2018.1478157
pubmed: 29775403
Pinzi V, Marchetti M, De Martin E, Cuccarini V, Tramacere I, Ghielmetti F, Fumagalli ML, Iezzoni C, Fariselli L (2020) Multisession radiosurgery for intracranial meningioma treatment: study protocol of a single arm, monocenter, prospective trial. Radiat Oncol 15(1):26. https://doi.org/10.1186/s13014-020-1478-7
doi: 10.1186/s13014-020-1478-7
pubmed: 32000819
pmcid: 6993396
Rogers L, Zhang P, Vogelbaum MA et al (2018) Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg 129:35–47
doi: 10.3171/2016.11.JNS161170
Momin AA, Shao J, Soni P, Almeida JP, Suh JH, Murphy ES, Chao ST, Angelov L, Mohammadi AM, Barnett GH, Recinos PF, Kshettry VR (2021) Outcomes of salvage radiation for recurrent World Health Organization grade II meningiomas: a retrospective cohort study. J Neurooncol 152(2):373–382. https://doi.org/10.1007/s11060-021-03711-z
doi: 10.1007/s11060-021-03711-z
pubmed: 33590402
Mahase SS, Roth O’Brien DA, No D, Roytman M, Skafida ME, Lin E, Karakatsanis NA, Osborne JR, Brandmaier A, Pannullo SC, Ramakrishna R, Stieg PE, Knisely JPS, Ivanidze J (2021) [
doi: 10.1093/noajnl/vdab012
pubmed: 33738446
pmcid: 7954102
Nassiri F, Wang JZ, Singh O, Karimi S, Dalcourt T, Ijad N, Pirouzmand N, Ng HK, Saladino A, Pollo B, Dimeco F, Yip S, Gao A, Aldape KD, Zadeh G (2021) International Consortium on Meningiomas. Loss of H3K27me3 in meningiomas. Neuro Oncol 23(8):1282–1291. https://doi.org/10.1093/neuonc/noab036
doi: 10.1093/neuonc/noab036
pubmed: 33970242
Al-Rashed M, Foshay K, Abedalthagafi M (2020) Recent advances in meningioma immunogenetics. Front Oncol 9:1472. https://doi.org/10.3389/fonc.2019.01472
doi: 10.3389/fonc.2019.01472
pubmed: 31970090
pmcid: 6960175